%0 Journal Article %A M. Markman %T Maintenance chemotherapy in advanced ovarian cancer: the US experience %D 2008 %R 10.1111/j.1525-1438.2007.01104.x %J International Journal of Gynecologic Cancer %P 40-43 %V 18 %N Suppl 1 %X The somewhat controversial results of a Southwest Oncology Group/Gynecologic Oncology Group phase 3 randomized trial have revealed that a maintenance strategy consisting of 12 cycles of single-agent paclitaxel (175 mg/m2 over 3 h every 28 days), delivered to women with advanced ovarian cancer who have achieved a clinically defined complete response to primary platinum–paclitaxel chemotherapy, significantly improves progression-free survival compared to delivery of three cycles of the same treatment regimen. While it is not possible to provide a definitive statement regarding the impact of this management approach on overall survival, in an exploratory analysis, patients who initiated this study with a baseline CA-125 level ≤10 units/mL and were treated with the 12-cycle maintenance program experienced a statistically significant improvement in survival. An ongoing Gynecologic Oncology Group trial in the United States will hopefully provide a definitive answer to the question of the impact of this novel strategy on outcome in ovarian cancer. %U https://ijgc.bmj.com/content/ijgc/18/Suppl_1/40.full.pdf